Navigation Links
Cypher Sirolimus-eluting Coronary Stent Had Similar Results to,Bypass Surgery in Long-Term Study of Patients With Multi-Vessel,Coronary Artery Disease

NEW ORLEANS, March 26, 2007 /PRNewswire-FirstCall/ -- Three-year follow-up data presented today at the of Cardiology's 56th Annual Scientific Session (ACC.07) showed that the CYPHER(R) Sirolimus-eluting Coronary Stent had results comparable to coronary artery bypass grafting (CABG or bypass surgery) in patients with blockages in two or more vessels, one of the most complex patient populations examined to date with any drug-eluting stent.

The Arterial Revascularization Therapy Study II (ARTS II Study) is an extension of the ARTS I Study, which was conducted in 1997 and compared the results of bare-metal stents (BMS) to those obtained with bypass surgery. Sponsored by Cordis Corporation, the ARTS II Study includes 607 patients from 45 European centers treated with the CYPHER(R) Stent. Investigators compared the findings for these patients to those from the ARTS I Trial, which included 605 patients treated with bypass surgery and 600 treated with a BMS.

After three years of patient follow-up, the ARTS II Study continued to show similar rates of survival from major adverse cardiac and cerebrovascular events (MACCE) for the CYPHER(R) Stent and bypass surgery. This finding is significant as MACCE -- comprised of death, stroke, myocardial infarction (heart attack) and the need for revascularization (re-treatment) of the blocked artery -- was the primary endpoint of the ARTS II Study, which was designed to assess whether the CYPHER(R) Stent was as effective as bypass surgery.

"Physicians are continuing to evaluate how to best treat and improve the quality-of-life of patients with multi-vessel coronary artery disease," said Patrick W. Serruys, M.D., Ph.D., from Thoraxcenter, Erasmus Medical Center in The Netherlands, and the presenter of the findings today at ACC.07. "The ARTS II three-year data suggest that percutaneous procedures using the CYPHER(R) Stent provided similar results to bypass surgery in these patients and are much less invasive."

Specifically, 80.6 percent of the patients who received the CYPHER(R) Stent remained free of MACCE, compared to 83.8 percent of the patients in the bypass surgery arm. Additionally, the CYPHER(R) Stent performed considerably better than the BMS arm in the same endpoint, as 66.0 percent of the patients who received a BMS did not experience a MACCE event after three years. The difference between the CYPHER(R) Stent arm and the BMS arm reached statistical significance (p<0.001).

The severe event rate (a composite for death, stroke and heart attack) for the CYPHER(R) Stent was compared with both the bypass surgery and BMS. The three-year follow-up data showed that 92.0 percent of the patients who received the CYPHER(R) Stent had survived and had not experienced a stroke or a heart attack, compared with 89.1 percent of the patients in the bypass surgery arm and 87.2 percent of the patients in the BMS arm. The difference between the CYPHER(R) Stent arm and the BMS arm reached statistical significance (p=0.004).

"More than 25 years ago, balloon angioplasty transformed the treatment paradigm for patients with coronary artery disease," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Cardiology Division of Cordis Corporation. "The three-year results of the ARTS II Study indicated that balloon angioplasty combined with the CYPHER(R) Stent was as good a treatment as bypass surgery and provided better outcomes than BMS implantation in patients with multi-vessel disease."

The ARTS II Study investigators also reported stent thrombosis rates using the Academic Research Consortium (ARC) definition. The definite stent thrombosis rate for the CYPHER(R) Stent at 30 days was 1 percent, lower than the 2.8 percent rate found in the BMS arm. The cumulative rates of definite and definite/probable stent thrombosis for the CYPHER(R) Stent at three-year follow-up were 3.3 percent and 5 .3 percent, respectively. Three-year stent thrombosis comparisons with the BMS arm were not possible, as the ARTS I Study did not track stent thrombosis rates beyond 30 days.

The CYPHER(R) Stent does not have an approved indication in the United States for patients with multi-vessel disease.

About the CYPHER(R) Stent

The CYPHER(R) Stent has been chosen by cardiologists worldwide to treat approximately three million patients with coronary artery disease. The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 70 studies that examine the performance of the CYPHER(R) Stent in a broad range of patients.

Developed and manufactured by Cordis Corporation, the CYPHER(R) Stent is currently available in more than 80 countries and has the broadest clinical experience and longest-term clinical follow-up of any drug-eluting stent. The next version of sirolimus-eluting stent, the CYPHER(R) SELECT(TM) Sirolimus- eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The CYPHER(R) SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many markets outside the United States.

For more complete information on indications, contraindications, warnings and precautions, see the Instructions for Use available at www.cypherstent.com.

About Cordis Corporation

Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at www.cordis.com.

*Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). Rapamune is a trademark of Wyeth Pharmaceuticals.

CONTACT: Mariela Melendez, Cordis Corporation, +1-786-313-2776, Cell:+1-786-218-4084, ; Todd Ringler, Edelman,+1-781-599-7542, Cell: +1-617-872-1235, mmelen10@crdus.jnj.com todd.ringler@edelman.com

Web site: http://www.cordis.com/http://www.cypherstent.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
2. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
3. New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk
4. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
5. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
6. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
9. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
10. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
11. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Südkorea, 23. Februar 2017 LG Innotek hat ... vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der ... im Bereich zwischen 200 und 280 nm und eignet sich ... indem es ihre DNA zerstört. Das Produkt von LG ... ...
(Date:2/23/2017)... ITL Limited, ( ASX: ITD ), an innovative diversified healthcare company, ... 31 December 2016 compared with the previous corresponding period. A full ... here . Highlights Profit ... Earnings per share of 2.2 cents (Dec 2015: 1.2 cents; ... up 11%) Profit before tax of $2.12m (Dec ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of the ... their offering. ... research Menopause Drugs Price Analysis and Strategies - 2016, provides drug pricing ... the following questions: What are the key ... in the Global Menopause market? What are the unit ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and ... Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when he ... He explains that the Bible details the current times so plainly that anyone ...
(Date:2/24/2017)... ... , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently ... as the Chairman of the Management Committee when IFN was originally formed in 2002 ... of investor/owners and development of the business plan. He became the first paid ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... marketing services, which specializes in thought leadership , media relations, social media, ... and services that will be powered through Act-On, an intuitive marketing automation platform. ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... again hosted their Military Wedding Giveaway, with the winning couple announced on Feb. ... with services generously donated from local vendors: A Matter of Taste, Ryan Rousseau ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... jointly issued a letter to withdraw previous guidance issued by the ... identity. The guidance issued in May 2016 by the Obama Administration came in ...
Breaking Medicine News(10 mins):